Suleiman-El-Hattab syndrome: a histone modification disorder caused by TASP1 deficiency.
Journal
Human molecular genetics
ISSN: 1460-2083
Titre abrégé: Hum Mol Genet
Pays: England
ID NLM: 9208958
Informations de publication
Date de publication:
10 09 2022
10 09 2022
Historique:
received:
04
01
2022
revised:
04
04
2022
accepted:
23
04
2022
pubmed:
6
5
2022
medline:
20
9
2022
entrez:
5
5
2022
Statut:
ppublish
Résumé
TASP1 encodes an endopeptidase activating histone methyltransferases of the KMT2 family. Homozygous loss-of-function variants in TASP1 have recently been associated with Suleiman-El-Hattab syndrome. We report six individuals with Suleiman-El-Hattab syndrome and provide functional characterization of this novel histone modification disorder in a multi-omics approach. Chromosomal microarray/exome sequencing in all individuals. Western blotting from fibroblasts in two individuals. RNA sequencing and proteomics from fibroblasts in one individual. Methylome analysis from blood in two individuals. Knock-out of tasp1 orthologue in zebrafish and phenotyping. All individuals had biallelic TASP1 loss-of-function variants and a phenotype including developmental delay, multiple congenital anomalies (including cardiovascular and posterior fossa malformations), a distinct facial appearance and happy demeanor. Western blot revealed absence of TASP1. RNA sequencing/proteomics showed HOX gene downregulation (HOXA4, HOXA7, HOXA1 and HOXB2) and dysregulation of transcription factor TFIIA. A distinct methylation profile intermediate between control and Kabuki syndrome (KMT2D) profiles could be produced. Zebrafish tasp1 knock-out revealed smaller head size and abnormal cranial cartilage formation in tasp1 crispants. This work further delineates Suleiman-El-Hattab syndrome, a recognizable neurodevelopmental syndrome. Possible downstream mechanisms of TASP1 deficiency include perturbed HOX gene expression and dysregulated TFIIA complex. Methylation pattern suggests that Suleiman-El-Hattab syndrome can be categorized into the group of histone modification disorders including Wiedemann-Steiner and Kabuki syndrome.
Sections du résumé
BACKGROUND
TASP1 encodes an endopeptidase activating histone methyltransferases of the KMT2 family. Homozygous loss-of-function variants in TASP1 have recently been associated with Suleiman-El-Hattab syndrome. We report six individuals with Suleiman-El-Hattab syndrome and provide functional characterization of this novel histone modification disorder in a multi-omics approach.
METHODS
Chromosomal microarray/exome sequencing in all individuals. Western blotting from fibroblasts in two individuals. RNA sequencing and proteomics from fibroblasts in one individual. Methylome analysis from blood in two individuals. Knock-out of tasp1 orthologue in zebrafish and phenotyping.
RESULTS
All individuals had biallelic TASP1 loss-of-function variants and a phenotype including developmental delay, multiple congenital anomalies (including cardiovascular and posterior fossa malformations), a distinct facial appearance and happy demeanor. Western blot revealed absence of TASP1. RNA sequencing/proteomics showed HOX gene downregulation (HOXA4, HOXA7, HOXA1 and HOXB2) and dysregulation of transcription factor TFIIA. A distinct methylation profile intermediate between control and Kabuki syndrome (KMT2D) profiles could be produced. Zebrafish tasp1 knock-out revealed smaller head size and abnormal cranial cartilage formation in tasp1 crispants.
CONCLUSION
This work further delineates Suleiman-El-Hattab syndrome, a recognizable neurodevelopmental syndrome. Possible downstream mechanisms of TASP1 deficiency include perturbed HOX gene expression and dysregulated TFIIA complex. Methylation pattern suggests that Suleiman-El-Hattab syndrome can be categorized into the group of histone modification disorders including Wiedemann-Steiner and Kabuki syndrome.
Identifiants
pubmed: 35512351
pii: 6577269
doi: 10.1093/hmg/ddac098
pmc: PMC9476618
doi:
Substances chimiques
Transcription Factor TFIIA
0
Histone Methyltransferases
EC 2.1.1.-
Endopeptidases
EC 3.4.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3083-3094Subventions
Organisme : NEI NIH HHS
ID : R01 EY032976
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Références
Nat Genet. 2017 Feb;49(2):223-237
pubmed: 27992417
AJR Am J Roentgenol. 1989 Dec;153(6):1289-300
pubmed: 2816648
Am J Hum Genet. 2017 May 4;100(5):773-788
pubmed: 28475860
Hum Mol Genet. 2015 Aug 1;24(15):4443-53
pubmed: 25972376
Nat Commun. 2015 Dec 22;6:10207
pubmed: 26690673
Nat Commun. 2016 Nov 04;7:13326
pubmed: 27811911
Mol Cell Biol. 2006 Apr;26(7):2728-35
pubmed: 16537915
Brain. 2021 Mar 3;144(2):411-419
pubmed: 33313762
Genes Dev. 2019 Jan 1;33(1-2):61-74
pubmed: 30573454
Nat Genet. 2010 Sep;42(9):790-3
pubmed: 20711175
Genome Res. 2015 Oct;25(10):1473-81
pubmed: 26430157
Nat Commun. 2017 Jun 12;8:15824
pubmed: 28604674
Hum Mutat. 2019 Nov;40(11):1985-1992
pubmed: 31209944
Mol Cell Oncol. 2015 Jan 23;2(4):e999513
pubmed: 27308523
J Clin Invest. 2015 Mar 2;125(3):1203-14
pubmed: 25664857
Am J Hum Genet. 2016 Dec 1;99(6):1377-1387
pubmed: 27839873
Nat Med. 2019 Jan;25(1):60-64
pubmed: 30617323
Genes Dev. 2006 Sep 1;20(17):2397-409
pubmed: 16951254
Cell. 2003 Oct 31;115(3):293-303
pubmed: 14636557
Am J Hum Genet. 2020 Mar 5;106(3):356-370
pubmed: 32109418
Clin Genet. 2017 Apr;91(4):616-622
pubmed: 27717089
Am J Hum Genet. 2019 Sep 5;105(3):606-615
pubmed: 31474318
Genome Med. 2017 Sep 21;9(1):83
pubmed: 28934986
EMBO J. 2004 Aug 4;23(15):3083-91
pubmed: 15257296
Am J Hum Genet. 2018 Dec 6;103(6):907-917
pubmed: 30503520
Hum Mol Genet. 2015 Aug 1;24(15):4340-52
pubmed: 25954033
Am J Hum Genet. 2012 Aug 10;91(2):358-64
pubmed: 22795537
Hum Mutat. 2015 Oct;36(10):928-30
pubmed: 26220891
Nat Commun. 2020 Nov 30;11(1):6087
pubmed: 33257696
Annu Rev Biochem. 2012;81:65-95
pubmed: 22663077
Radiographics. 1993 Nov;13(6):1211-31
pubmed: 8031352